Loading clinical trials...
Loading clinical trials...
An open-label follow-on safety study of CDP870 (400 mg every 4 weeks) in patients with Crohn's Disease who have completed a 26-week blinded study (CDP870-031 \[NCT00152490\] or CDP870-032 \[NCT0015242...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
UCB Pharma SA
NCT04844606 · Ulcerative Colitis, Ulcerative Colitis Chronic, and more
NCT06180382 · Crohn's Disease
NCT06226883 · Inflammatory Bowel Diseases, Crohn's Disease
NCT07184931 · Crohn's Disease
NCT06918808 · Perianal Fistula Due to Crohn's Disease
45102
Birmingham, Alabama
45028
Huntsville, Alabama
45144
Tucson, Arizona
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions